INT119062

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.49
First Reported 2004
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 12
Total Number 13
Disease Relevance 13.70
Pain Relevance 1.36

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleoplasm (BRCA1) chromosome segregation (BRCA1) intracellular (BRCA1)
enzyme binding (BRCA1) DNA binding (BRCA1) protein complex (BRCA1)
Anatomy Link Frequency
filament 1
iris 1
BRCA1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Chronic pancreatitis 1 99.84 Very High Very High Very High
cytokine 91 95.56 Very High Very High Very High
endometriosis 1 94.48 High High
Inflammatory response 17 94.04 High High
cva 24 91.60 High High
transdermal 1 90.90 High High
tolerance 14 90.32 High High
imagery 55 85.04 High High
Inflammation 107 81.04 Quite High
corticosteroid 1 68.64 Quite High
Disease Link Frequency Relevance Heat
Immune Reconstitution Inflammatory Syndrome 475 100.00 Very High Very High Very High
Pancreatitis 1 99.84 Very High Very High Very High
Hyperplasia 14 99.64 Very High Very High Very High
Breast Cancer 762 99.62 Very High Very High Very High
Disease 196 98.88 Very High Very High Very High
Breast Disease 9 98.88 Very High Very High Very High
Noninfiltrating Intraductal Carcinoma 64 98.52 Very High Very High Very High
Acquired Immune Deficiency Syndrome Or Hiv Infection 136 98.44 Very High Very High Very High
Skin Cancer 1 98.36 Very High Very High Very High
Ductal Carcinoma 1 98.24 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Only a relatively small proportion of breast cancers are caused by the loss of BRCA1 or BRCA2 function; most arise as a result of somatic mutation or changes in expression of a number of other genes.
Negative_regulation (loss) of BRCA1 associated with breast cancer
1) Confidence 0.49 Published 2008 Journal Breast Cancer Res Section Body Doc Link PMC2397525 Disease Relevance 0.60 Pain Relevance 0
The exclusion criteria for randomisation were:

• For the placebo controlled components: oral or transdermal HRT use in the last six months, ever use of HRT implant in women with a uterus, HRT implant inserted in last eight months in women with a hysterectomy. • History of endometriosis (hysterectomised or non-hysterectomised woman) or endometrial hyperplasia in a woman with a uterus. • History of invasive breast cancer, lobular carcinoma in-situ (LCIS), ductal carcinoma in-situ (DCIS), Paget's disease of the nipple or atypical hyperplasia of the breast. • Known BRCA1 or BRCA2 mutation carrier. • History of melanoma. • Invasive cancer at any other site apart from basal and squamous cell skin cancer within the last 10 years. • History of meningioma. • Myocardial infarction, cerebrovascular accident, sub-arachnoid haemorrhage or transient ischaemic attack within the last six months. • History of currently active liver disease or chronic liver disease but excluding Hepatitis A unless currently active. • Evidence of severe current renal impairment. • History of gall bladder disease in a woman who had not had a cholecystectomy or of gallstones following a cholecystectomy. • History of deep vein thrombosis, pulmonary embolism or retinal vein occlusion. • Positive thrombophilia screen (Factor V Leiden or prothrombin mutations, Protein C, Protein S or anti-thrombin III deficiencies, APC resistance, dysfibrinogenaemia or antiphospholipid antibodies). • Otosclerosis. • Porphyria. • History of hepatitis B, hepatitis C or HIV (not an exclusion in New Zealand). • Currently pregnant. • Currently taking or has taken contraceptive drugs in the last 12 months. • Current triglyceride level (fasting) > 5.5 mmol/l. • Active participant in any other intervention trial likely to affect trial outcomes. • Taking tamoxifen, toremifene, raloxifene or any other selective oestrogen receptor modulator (SERM). • Other conditions/circumstances where the general practitioner judged that it would not be possible to obtain fully informed consent and/or successfully complete trial procedures.


Negative_regulation (Known) of BRCA1 associated with porphyria, endometriosis (extended), cv general 4 under development, skin cancer, hyperplasia, liver disease, endometriosis, conductive hearing loss, hepatitis, brain tumor, lobular carcinoma, thrombophilia, gallbladder disease, gallstones, hepatitis a virus infection, disease, retinal vein occlusion, thrombosis, pulmonary embolism, ductal carcinoma, transdermal, cancer, basal and squamous cell skin cancer, acquired immune deficiency syndrome or hiv infection, noninfiltrating intraductal carcinoma, cva, reprotox - general 1 and myocardial infarction
2) Confidence 0.41 Published 2007 Journal BMC Womens Health Section Body Doc Link PMC1828722 Disease Relevance 2.55 Pain Relevance 0.22
This was diagnosed twenty-seven years after risk-reducing surgery (ovarian ablation and mastectomy) for a BRCA1 mutation in the context of breast disease management.
Negative_regulation (reducing) of BRCA1 associated with breast disease
3) Confidence 0.39 Published 2007 Journal World J Surg Oncol Section Body Doc Link PMC2075500 Disease Relevance 1.44 Pain Relevance 0.10
Down-regulation of BRCA1 in chronic pancreatitis and sporadic pancreatic adenocarcinoma.
Negative_regulation (Down-regulation) of BRCA1 associated with adenocarcinoma and chronic pancreatitis
4) Confidence 0.37 Published 2004 Journal Clin. Cancer Res. Section Title Doc Link 15173085 Disease Relevance 0.56 Pain Relevance 0.10
Cells deficient in BRCA1 and BRCA2 are extremely sensitive to DNA-damaging agents and are defective in repairing DNA double-strand breaks by homologous recombination, being impaired in the recruitment and filament formation of the recombination protein RAD51 [9,10].
Negative_regulation (defective) of BRCA1 in filament
5) Confidence 0.36 Published 2008 Journal Breast Cancer Res Section Body Doc Link PMC2397525 Disease Relevance 0.45 Pain Relevance 0
However, deficiencies remain in our understanding of how BRCA1 or BRCA2 dysfunction causes breast cancer, for example, it is unclear why BRCA1 deficiency is associated with triple-negative (basal-like) breast cancer.
Negative_regulation (deficiency) of BRCA1 associated with breast cancer
6) Confidence 0.36 Published 2008 Journal Breast Cancer Res Section Body Doc Link PMC2397525 Disease Relevance 0.72 Pain Relevance 0
However, alterations in DNA repair caused by defects in BRCA1 and BRCA2 may enhance the sensitivity of BRCA-positive tumors to platinum agents such as cisplatin and carboplatin, which cross-link DNA and interfere with replication [35].
Negative_regulation (defects) of BRCA1 associated with cancer
7) Confidence 0.33 Published 2010 Journal Current Genomics Section Body Doc Link PMC2878980 Disease Relevance 0.64 Pain Relevance 0
Loss of heterozigosity and mutations BRCA1 and BRCA2 leading to inactivation of other genes, has been described in familial ovarian cancers [55].
Negative_regulation (Loss) of BRCA1 associated with ovarian cancer
8) Confidence 0.30 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2798669 Disease Relevance 0.94 Pain Relevance 0
BRCA2 tumours expressed cyclin D1 and D3, cyclin D kinase (CDK) 4 and the CDK inhibitors, p16, p21, and p27, which were all downregulated in BRCA1.
Negative_regulation (downregulated) of BRCA1 associated with cancer
9) Confidence 0.24 Published 2006 Journal Proteome Sci Section Body Doc Link PMC1456950 Disease Relevance 1.16 Pain Relevance 0.11
This 'paradoxical worsening' could also be attributable to additional presence of defective FOXP3+ gene among IRIS developers.
Negative_regulation (presence) of IRIS associated with immune reconstitution inflammatory syndrome
10) Confidence 0.24 Published 2007 Journal AIDS Res Ther Section Body Doc Link PMC2216023 Disease Relevance 1.08 Pain Relevance 0.41
The biomarkers identified here, although requiring validation, may help target interventions to decrease IRIS risk, such as (1) early adjunctive GM-CSF or IFN-?
Negative_regulation (decrease) of IRIS associated with immune reconstitution inflammatory syndrome
11) Confidence 0.07 Published 2010 Journal PLoS Medicine Section Body Doc Link PMC3014618 Disease Relevance 0.88 Pain Relevance 0.13
Overall, 45% of the patients developed IRIS.
Negative_regulation (developed) of IRIS associated with immune reconstitution inflammatory syndrome
12) Confidence 0.07 Published 2010 Journal PLoS Medicine Section Abstract Doc Link PMC3014618 Disease Relevance 2.69 Pain Relevance 0.29
It has been shown that inhibition of bone morphogenetic protein (BMP) signaling [5] and wingless and integration (Wnt) signaling [6] in dorsal iris after dedifferentiation could be important to determine lens regeneration from dorsal iris.
Negative_regulation (inhibition) of iris in iris
13) Confidence 0.01 Published 2010 Journal Molecular Vision Section Body Doc Link PMC2956703 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox